Demoly Pascal, Passalacqua Gianni, Calderon Moises A, Yalaoui Tarik
Allergy Division, Pulmonology Department, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France.
Allergy and Respiratory Diseases, IRCCS San Martino-IST, University of Genoa, Genoa, Italy.
Clin Transl Allergy. 2015 Dec 23;5:44. doi: 10.1186/s13601-015-0088-1. eCollection 2015.
Sublingual immunotherapy (SLIT) is an effective and well-tolerated method of treating allergic respiratory diseases associated with seasonal and perennial allergens. In contrast to the subcutaneous route, SLIT requires a much greater amount of antigen to achieve a clinical effect. Many studies have shown that SLIT involves a dose-response relationship, and therefore it is important to use a proven clinically effective dose from the onset of treatment, because low doses are ineffective and very high doses may increase the risk of side effects. A well-defined standardization of allergen content is also crucial to ensure consistent quality, potency and appropriate immunomodulatory action of the SLIT product. Several methods of measuring antigenicity are used by manufacturers of SLIT products, including the index of reactivity (IR), standardized quality tablet unit, and bioequivalent allergy unit. A large body of evidence has established the 300 IR dose of SLIT as offering optimal efficacy and tolerability for allergic rhinitis due to grass and birch pollen and HDM, and HDM-induced moderate, persistent allergic asthma. The 300 IR dose also offers consistency of dosing across a variety of different allergens, and is associated with higher rates of adherence and patient satisfaction. Studies in patients with grass pollen allergies showed that the 300 IR dose has a rapid onset of action, is effective in both adults and children in the short term and, when administered pre-coseasonally in the long term, and maintains the clinical benefit, even after cessation of treatment. In patients with HDM-associated AR and/or asthma, the 300 IR dose also demonstrated significant improvements in symptoms and quality of life, and significantly decreased use of symptomatic medication. The 300 IR dose is well tolerated, with adverse events generally being of mild or moderate severity, declining in frequency and severity over time and in the subsequent courses. We discuss herein the most important factors that affect the selection of the optimal dose of SLIT with natural allergens, and review the rationale and evidence supporting the use of the 300 IR dose.
舌下免疫疗法(SLIT)是一种治疗与季节性和常年性过敏原相关的过敏性呼吸道疾病的有效且耐受性良好的方法。与皮下途径相比,SLIT需要更大剂量的抗原才能达到临床效果。许多研究表明,SLIT存在剂量反应关系,因此从治疗开始就使用经证实的临床有效剂量非常重要,因为低剂量无效,而非常高的剂量可能会增加副作用风险。明确界定过敏原含量的标准化对于确保SLIT产品的质量、效力和适当的免疫调节作用的一致性也至关重要。SLIT产品制造商使用多种测量抗原性的方法,包括反应性指数(IR)、标准化质量片剂单位和生物等效过敏单位。大量证据表明,对于由草花粉、桦树花粉和屋尘螨引起的过敏性鼻炎以及屋尘螨诱发的中度持续性过敏性哮喘,SLIT的300 IR剂量具有最佳疗效和耐受性。300 IR剂量在各种不同过敏原的给药方面也具有一致性,并且与更高的依从率和患者满意度相关。对草花粉过敏患者的研究表明,300 IR剂量起效迅速,在短期对成人和儿童均有效,并且在长期季前给药时,即使在治疗停止后仍能维持临床益处。在患有屋尘螨相关变应性鼻炎和/或哮喘的患者中,300 IR剂量也显示出症状和生活质量的显著改善,以及对症药物使用的显著减少。300 IR剂量耐受性良好,不良事件一般为轻度或中度严重程度,随着时间推移和后续疗程,其频率和严重程度会下降。我们在此讨论影响选择天然过敏原SLIT最佳剂量的最重要因素,并回顾支持使用300 IR剂量的基本原理和证据。